Clinical Trial Update: Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) [Phase 2]

View source ↗

Summary

A multicenter Phase 2 study evaluating abiraterone acetate 250 mg without LHRH analogs for hormonal intensification in prostate cancer. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: SMED Clinical Research | Conditions: Prostate Cancer (Diagnosis) | Phase 2 | Status: RECRUITING